Incyte Corporation

INCY 
(NASDAQ) 
 
$ 86.07 <%= Resources.Global.txtUp %>
Updated 20/08/2019
Change % 2.34% Stock price increasing
Change 1.97 Stock price increasing
Volume 489,965
High $ 86.11
Low $ 0
Open $ 84.75
ISIN
Prev close $ 84.10
# of shares 215.07M
Market cap 18,511M USD
Intraday

Market closed
Incyte Corporation
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  86.07 6.8% Stock price increasing 5.3% Stock price increasing 8.9% Stock price increasing 1.4% Stock price increasing 23.9% Stock price increasing
Powered by TradingView

News about Incyte Corporation

  • English
  • Regulatory news

Company profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 August 2019 00:12:00
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190819.1 - EUROWEB3 - 2019-08-22 01:12:00 - 2019-08-22 00:12:00 - 1000 - Website: OKAY